LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
STANDARD BIOTOOLS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.64+0.01 (+2.27%)
Close on Oct 19, 2026
- Market cap
- $251.45M
- P/E (TTM)
- 2.9
- Dividend yield
- –
Standard Biotools statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Market Cap | $252.55M | $166.30M |
| Enterprise Value | -$224.17M | $88.19M |
| PE Ratio | 2.92 | 20.44 |
| PS Ratio | 2.99 | 3.65 |
| PB Ratio | 0.47 | 2.03 |
| P/TBV Ratio | 0.47 | 2.29 |
Enterprise value
| Measure | Standard Biotools | Industry median |
|---|---|---|
| EV / Sales | -2.65 | 2.51 |
Income (trailing twelve months)
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Revenue | $84.60M | $58.34M |
| Gross Profit | $42.71M | $105.94M |
| Operating Income | -$95.47M | -$21.40M |
| Pretax Income | -$90.98M | -$14.34M |
| Net Income | $84.91M | -$22.46M |
| EBITDA | -$89.97M | -$16.91M |
| EPS (Diluted) | $0.22 | -$0.83 |
Margins
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Gross Margin | 50.5% | 52.9% |
| Operating Margin | -112.8% | -44.0% |
| Pretax Margin | -107.5% | -13.3% |
| Profit Margin | 100.4% | -40.2% |
| EBITDA Margin | -106.4% | -30.2% |
| FCF Margin | -97.6% | -9.27% |
Returns
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Return on Equity (ROE) | 17.6% | -53.2% |
| Return on Assets (ROA) | 14.3% | -40.9% |
| Return on Invested Capital (ROIC) | -60.8% | -32.4% |
| Return on Capital Employed (ROCE) | -16.7% | -38.1% |
Growth
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -4.78% | 5.96% |
| Revenue Growth (3Y CAGR) | -4.49% | 2.25% |
| Revenue Growth (5Y CAGR) | -9.19% | 6.48% |
Balance sheet
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $476.72M | $61.43M |
| Net Cash (Debt) | $476.72M | $15.35M |
| Net Cash Per Share | $1.21 | $0.66 |
| Equity (Book Value) | $539.97M | $49.09M |
| Book Value Per Share | $1.38 | $1.37 |
| Tangible Book Value | $539.97M | $23.52M |
| Working Capital | $460.07M | $76.81M |
Financial position
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Current Ratio | 9.10 | 3.34 |
| Quick Ratio | 8.67 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Operating Cash Flow | -$80.30M | -$12.35M |
| Capital Expenditures | -$2.28M | -$1.08M |
| Free Cash Flow | -$82.58M | -$20.22M |
| FCF Per Share | -$0.21 | -$0.42 |
Efficiency
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Asset Turnover | 0.14 | 0.39 |
| Inventory Turnover | 2.03 | 2.70 |
| Revenue Per Employee | $217.47K | $404.87K |
| Profits Per Employee | $218.27K | -$703.34K |
| Employee Count | 389 | 74 |
Dividends and yields
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Earnings Yield | 33.6% | -23.3% |
| FCF Yield | -32.7% | -8.72% |
Shares
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Shares Outstanding | 392,579,000 | 58,127,000 |
| Shares Change (YoY) | 2.78% | 10.9% |
| Shares Change (QoQ) | 0.51% | 0.54% |
| Float | 117,017,000 | 49,136,700 |
| Shares Held by Insiders | 70.2% | 11.6% |
| Shares Held by Institutions | 75.4% | 59.4% |
Taxes
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Income Tax | -$37.05M | $79.87K |
Scores
| Measure | Standard Biotools | Industry median |
|---|---|---|
| Graham Number | $2.61 | $18.73 |
| Graham Upside | 305.6% | -45.1% |
| Altman Z-Score | -0.34 | -0.22 |
| Piotroski F-Score | 3 | 4 |
| Beneish M-Score | -3.05 | -2.62 |
Calculated by StockData from Standard Biotools's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.